BC Cancer Agency Protocol Summary for Treatment of Advanced Head and Neck Cancer Using CISplatin and Fluorouracil

**Protocol Code:**

HNSAVFUP

**Tumour Group:**

Head and Neck

**Contact Physician:**

Dr. Cheryl Ho

**ELIGIBILITY:**

- Locoregionally recurrent/metastatic head and neck cancer (salivary, squamous cell, nasopharyngeal or sinonasal undifferentiated carcinoma) with ECOG status 0-2
- normal hepatic and renal function
- adequate marrow function
- Intravascular device (e.g. PORT-A-CATH® or PICC® line) is highly recommended

**TESTS:**

- Baseline: CBC & diff, platelets, creatinine, electrolytes, serum calcium, serum magnesium, serum albumin, AST, bilirubin
- Before each treatment: CBC & diff, creatinine
- If clinically indicated: Bilirubin

**PREMEDICATION:**

- Ondansetron 8 mg PO and dexamethasone 8 mg po 30 minutes pre-CISplatin each day at least every 12 hours regularly during each day
- Optional: Aprepitant 125 mg PO pre-chemotherapy day 1 and 80 mg PO once daily in the morning on Days 2 and 3
- Prochlorperazine is usually sufficient after 3-5 days of ondansetron and dexamethasone

**TREATMENT:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>fluorouracil</td>
<td>1,000 mg/m² /day for 4 days</td>
<td>IV in D5W to a total volume of 192 mL by continuous infusion at 2 mL/h via appropriate infusor device*</td>
</tr>
<tr>
<td>(5FU)</td>
<td>(total dose = 4,000 mg/m² over 96 h)</td>
<td></td>
</tr>
<tr>
<td>CISplatin</td>
<td>25 mg/m² Daily for 3 to 4 days</td>
<td>IV in 100 mL NS over 30 min (use 250 mL NS if greater than 60 mg)</td>
</tr>
</tbody>
</table>

*Inpatients: 1,000 mg/m²/day in 1,000 mL D5W by continuous infusion daily over 24 h for 4 days
- The cycle is repeated every 4 weeks.

**DURATION OF THERAPY:**

BC Cancer Agency Protocol Summary HNSAVFUP 1/4

Warning: This information contained in these documents is a statement of consensus of BC Cancer Agency professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer Agency's terms of use available at www.bccancer.bc.ca/legal.htm
Treatment may continue for a total of 6 cycles or to patience tolerance.

**DOSE MODIFICATIONS:**

1. **Hematological**
   - Modify 5-Fluorouracil ONLY:
     
     | ANC (x 10^9/L) | Platelets (x 10^9/L) | Dose (Fluorouracil only) |
     |---------------|----------------------|--------------------------|
     | 1 to 1.5 or less than 1 | 75 to 100 or less than 75 | 750 mg/m^2 /d x 4 days |
     | less than 1 | less than 75 | 375 mg/m^2 /d x 4 days |

2. **Renal Toxicity**
   - Modify CISplatin dose according to renal function
     
     | Creatinine clearance (mL/min) | Dose (CISplatin only) |
     |-------------------------------|-----------------------|
     | greater than or equal to 60 | 100% |
     | 45 to 59 | 50% |
     | less than 45 | Delay x 1 week |

Calculation of the creatinine clearance rate (estimated using standard formula) should be done every cycle because patients who have lost weight may have normal serum creatinine, but have abnormal estimated creatinine clearance. If estimated creatinine clearance changes to less than 60 mL/min, dose reduction should be considered.

\[
\text{Creatinine clearance} = \frac{N^* \times (140-\text{age}) \times \text{weight (kg)}}{\text{Serum Creatinine micromol/L}}
\]

* for males N = 1.23, for females N = 1.04

The estimated GFR should be capped at 125 mL/min when it is used to calculate the initial CARBOplatin dose. When a nuclear renogram is available, this clearance would take precedence.
3. Neurotoxicity:

- Tinnitus, mild high frequency hearing loss, and delayed peripheral neuropathy may occur secondary to CISplatin. The latter are generally reversible with time. If clinically significant hearing loss or functionally significant peripheral neuropathy occurs, discontinue CISplatin only.
- CNS toxicity due to fluorouracil is infrequent, but would necessitate cessation of treatment

4. GI Toxicity:

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Grade</th>
<th>Description</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea and Vomiting</td>
<td>4</td>
<td>greater than 10 episodes in 24 h or needs parenteral support, dehydration</td>
<td>If not controlled by antiemetics, give 75% dose CISplatin or stop treatment</td>
</tr>
</tbody>
</table>

G.I. tract toxicity consisting of stomatitis or diarrhea and cramps suggestive of drug toxicity and is indication to stop therapy.

PRECAUTIONS:

1. **Nausea and vomiting** are common and patients should be treated with ondansetron and dexamethasone before at least every 12 hours regularly during this treatment (see premedication section)

2. **Renal toxicity** may occur with a salt and water losing nephropathy. Patients should be encouraged to maintain good oral hydration.

3. **Myocardial ischemia and angina occurs rarely in patients receiving fluorouracil or capecitabine.** Development of cardiac symptoms including signs suggestive of ischemia or of cardiac arrhythmia is an indication to discontinue treatment. If there is development of cardiac symptoms patients should have urgent cardiac assessment. Generally re-challenge with either fluorouracil or capecitabine is not recommended as symptoms potentially have a high likelihood of recurrence which can be severe or even fatal. Seeking opinion from cardiologists and oncologists with expert knowledge about fluorouracil or capecitabine toxicity is strongly advised under these circumstances. The toxicity should also be noted in the patient’s allergy profile.

4. **Possible drug interactions with fluorouracil and warfarin, phenytoin and fosphenytoin** have been reported and may occur at any time. Close monitoring is recommended (eg, for warfarin, monitor INR weekly during fluorouracil therapy and for 1 month after stopping fluorouracil).
Contact Dr. Cheryl Ho or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date activated: 1 Sep 2010

Date revised: 1 May 2013 (cardiac toxicity updated)

References: